Minocycline compounds and methods of use thereof

Inventors

Johnston, Sean M. • Arbeit, Robert D. • Bigger, Thomas J. • Molnar, Dennis P. • Tanaka, S. Ken

Assignees

Paratek Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9265740-B2

Patent

Publication Date

2016-02-23

Expiration Date


Abstract

Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, Enterococcus, or combinations thereof.

Core Innovation

The document describes 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline, or a salt thereof, for treating bacterial infections, including complicated skin and skin structure infections. It also describes pharmaceutical compositions of the compound or a salt thereof with a pharmaceutically acceptable carrier for oral or intravenous administration. The claimed treatment is associated with mild gastrointestinal adverse events.

The supplied content reports a Phase 2 comparison with linezolid, in which compound 1 achieves clinical success in clinically evaluable and microbiologically evaluable patients. Gastrointestinal adverse events are generally mild and do not lead to treatment discontinuation. The background section is not included in the supplied content, so the problem being solved is not explicitly described in patent.

Claims Coverage

The claims identify three inventive features covering an oral treatment method for complicated skin and skin structure infections, an oral pharmaceutical composition, and an intravenous pharmaceutical composition.

Oral treatment of complicated skin and skin structure infections

Orally administering 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof to a human subject with complicated skin and skin structure infections, with associated gastrointestinal adverse events described as mild.

Oral pharmaceutical composition

A pharmaceutical composition comprising 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof and a pharmaceutically acceptable carrier for oral administration.

Intravenous pharmaceutical composition

A pharmaceutical composition comprising 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof and a pharmaceutically acceptable carrier for intravenous administration.

The claims cover treatment of complicated skin and skin structure infections by oral administration, and pharmaceutical compositions for oral and intravenous administration.

Stated Advantages

Treatment-associated gastrointestinal adverse events are mild.

Treatment-associated gastrointestinal adverse events do not lead to discontinuation of therapy.

Documented Applications

Treatment of complicated skin and skin structure infections, including infections caused by Staphylococcus aureus, Streptococci, or both.

Oral and intravenous pharmaceutical compositions of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.